monoclonal antibody therapy
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 4 min read
Early functional testing could transform the future of antibody-based therapies — here’s how.
| 4 min read
Uniquity Bio seeks to investigate compounds that might otherwise sit on the shelf forever. Their lead compound appears poised to prove their model works.
| 8 min read
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
| 4 min read
Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.
Available on Demand
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.
Page 1 of 1 - 6 Total Items
